Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 30, 2025

In vivo screening of TCR-based chimeric antigen receptors for improved anti-tumor functionality

View Full Paper
Ask AI
Bookmark
Share

Authors

AZAndreas ZinggRRReto RitschardHTHelen Thut

Discussion

Loading...

Member takes

Overview

In vivo screening identifies TCR-based constructs with CD28 and CD27 costimulatory domains, improving efficacy in solid tumors.

Key Points

  • Conventional CAR-T therapy faces challenges in solid tumors due to antigen escape and T-cell exhaustion.
  • TRuCs, integrating TCR signaling with CD3ε, enhance T-cell activation and anti-tumor properties.
  • In vivo screenings revealed a TRuC variant with combined CD28 and CD27 costimulatory domains offering superior proliferation.
  • Optimized constructs demonstrated better anti-tumor efficacy in mouse models compared to standard CAR-T designs.

Cite This Study

Zingg et al. (2025) studied this question.

synapsesocial.com/papers/689a0945e6551bb0af8cef67https://doi.org/10.1101/2025.07.23.666356
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1TCR/CD3-based synthetic antigen receptors (TCC) convey superior antigen sensitivity combined with high fidelity of activation2024
  2. 2FcγR-driven chimeric receptor T cells in cancer therapy: a novel frontier in antibody-guided immunotherapy2026
  3. 3Abstract 5240: Novel CD3-Fusion Receptor enables combination of T-cell engagers and allogeneic CAR T cells to promote enhanced antitumor activity and overcome antigen escape2024
  4. 4Sensitive bispecific chimeric T cell receptors for cancer therapy2024 · 1 citations
  5. 5High-throughput single-cell screening of a cross-lineage CAR library for early-stage CAR design and candidate discovery2026